Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Metabolic-associated steatotic liver disease (MASLD) is a global health burden intricately linked to cardiovascular disease (CVD) through shared pathways-insulin resistance, dyslipidemia, and chronic inflammation. CVD has become the leading cause of mortality in MASLD, necessitating integrated management strategies. This review synthesizes evidence on bidirectional MASLD-CVD interactions and evaluates therapeutic approaches: Lifestyle modifications, pharmacotherapy (, GLP-1 receptor agonists, SGLT2 inhibitors, statins), and metabolic interventions. Despite progress, critical gaps persist in risk stratification tools, personalized treatment algorithms, and long-term outcomes of novel agents like resmetirom. A multidisciplinary care model, bridging hepatology and cardiology, is essential to address these challenges and improve patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304865 | PMC |
| http://dx.doi.org/10.4330/wjc.v17.i7.107751 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Defining non-invasive criteria for indicating drug therapy in metabolic-associated steatotic liver disease in clinical practice.
Clin Gastroenterol Hepatol
September 2025
CIBERehd, Spain; SeLiver group, Instituto de Biomedicina de Sevilla; Hospital Universitario Virgen del Rocío; Universidad de Sevilla. Electronic address:
Background: &Aim:Resmetirom is the first FDA-approved drug for metabolic-associated liver disease(MASLD) in F2-F3 patients with steatohepatitis. Non-invasive criteria have been proposed for initiating treatment; however, these have not been validated in clinical practice. We validated the proposed criteria and established new guidelines for initiating resmetirom treatment in clinical practice.
View Article and Find Full Text PDFAssociation between metabolic associated fatty liver disease and HCC risk after SVR in HCV patients: A systematic review and meta-analysis.
Clin Exp Hepatol
June 2025
Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Aim Of The Study: Chronic hepatitis C (CHC) infection remains one of the most prevalent chronic liver disease worldwide. A sustained virological response (SVR) can be achieved at high rates for CHC patients receiving direct-acting antivirals (DAAs). However, even small subsets of patients achieving SVR still have a risk of developing hepatocellular carcinoma (HCC).
View Article and Find Full Text PDFA potential age-independent MASLD-related liver fibrosis index based on metabolic profiling.
Sci Rep
September 2025
Department of Chemical Science and Technology, University of Rome "Tor Vergata", 00133, Rome, Italy.
The burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is of immediate concern, as its prevalence is increasing worldwide. MASLD often progresses to liver fibrosis, posing significant health risks. Age-independent, noninvasive tools to evaluate fibrosis are needed to improve diagnostic accuracy across all age groups.
View Article and Find Full Text PDFImmune metabolic changes identify causal candidate genes and enable diagnostic frameworks in MAFLD.
Sci Rep
August 2025
Department of Endocrinology and Metabolism, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Metabolic dysfunction-associated fatty liver disease (MAFLD), a global epidemic affecting 25% of adults, is driven by immune-metabolic dysregulation, yet the causal mechanisms linking immune cell-specific gene perturbations to disease progression remain unresolved. Current studies lack systematic integration of single-cell transcriptomics, causal inference, and functional validation to dissect actionable potential intervention targets. We combined peripheral blood mononuclear cells (PBMCs) single-cell RNA sequencing (scRNA-seq; GSE179886: 2 MAFLD vs.
View Article and Find Full Text PDFThe Significance of Enzymatic Cholestasis in Inflammatory Bowel Disease Patients for the Diagnosis of Primary Sclerosing Cholangitis-A Retrospective Study.
J Clin Med
August 2025
Department of Internal Medicine, Discipline of Gastroenterology and Hepatology, University of Medicine and Pharmacy Carol Davila, 020021 Bucharest, Romania.
This retrospective longitudinal study evaluated the significance of cholestasis syndrome and the diagnosis of primary sclerosing cholangitis (PSC) in inflammatory bowel disease (IBD) patients from a tertiary center in Romania. From 2011 to 2022, 3767 patients suspected for IBD were evaluated, with 2499 confirmed cases. Of these, 34 patients (1.
View Article and Find Full Text PDF